The company systematically screens human tumor cells to identify novel targets and analyze their mode of action. Their therapeutics focus on breaking down the resistance mechanisms of tumors against immune attack, which is often mediated by cell surface molecules that stimulate immune-inhibitory receptors on T cells. By neutralizing these negative interactions, iOmx aims to reactivate the host immune response and provide cancer immune-checkpoint therapy. Located in Martinsried/Munich, Germany, iOmx is a young start-up in the field of immuno-oncology, supported by a powerful technology platform and renowned investors. They are driving the development of a cutting-edge portfolio of early-stage immune-checkpoint drugs through pre-clinical and clinical stages.